VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.23 USD
-0.02 (-0.89%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.19 -0.04 (-1.79%) 5:00 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VYNE 2.23 -0.02(-0.89%)
Will VYNE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Other News for VYNE
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics announces granting of composition of matter patent for VYN202
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
12 Health Care Stocks Moving In Thursday's Intraday Session